Drugs / Ziprasidone
Ziprasidone
also known as
Geodon · ziprasidone hydrochloride · CP-88, 059-27 · CP-88,059-1 · CP-88059 · NSC-760351 · Zeldox · ZIP · +10 more
Small molecule targets DRD2, HTR2A, HTR2C via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | GEODON | — | 2004-08-19 – 2022-01-28 | fda.gov ↗ |
| Approved | US (FDA) | GEODON | — | 2001-02-05 | fda.gov ↗ |
Trials 80 · started per year
today
US approved 2001
2
3
8
14
5
5
12
2
7
3
4
2
3
2
1
2
1
2
1
1
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04587115 | Jun 2017 → Jun 2019 | drug dependence | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03781115 | Nov 2017 → Feb 2027 expected | schizophrenia | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02650102 | Jan 2013 → Dec 2016 | schizophrenia | Shanxi Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04975035 | Jan → Jul 2012 | schizophrenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Terminated | No outcome recorded |
| Phase 26 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT00633399 | Jul 2008 → Mar 2014 | major depressive disorder | Massachusetts General Hospital | Completed | Met primary |
| Phase 2 | NCT00635700 | Mar 2008 → Nov 2012 | psychotic disorder | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00676429 | Jul 2006 → Jun 2008 | conduct disorder, oppositional defiant disorder | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 2 | NCT00215150 | Nov 2004 → Dec 2008 | social phobia | Duke University | Completed | Missed primary |
| Phase 2 | NCT01006551 | Dec 2002 → Feb 2006 | schizophrenia | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT00208559 | Feb 2002 → Jun 2005 | autism | Drexel University College of Medicine | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00395031 | Sep 2003 → Jan 2010 | schizoaffective disorder, schizophrenia | Manhattan Psychiatric Center | Completed | No outcome recorded |
| Phase 328 trials · 4 met primary · 5 missed | ||||||
| Phase 3 | NCT03768726 | Dec 2018 → Jul 2020 | bipolar disorder | Viatris Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02075047 | May 2014 → Apr 2020 | bipolar I disorder | Viatris Inc. | Terminated | Met primary Stop: Enrollment |
| Phase 3 | NCT01765829 | Nov 2012 → Nov 2015 | psychotic disorder | Fundación Pública Andaluza Progreso y Salud | Unknown | No outcome recorded |
| Phase 3 | NCT01211522 | Dec 2011 → Aug 2017 | delirium, mental disorder | Vanderbilt University Medical Center | Completed | Missed primary |
| Phase 3 | NCT01113541 | Jul 2010 → Feb 2011 | bipolar disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01124877 | Jul 2010 → Oct 2011 | bipolar disorder | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00723606 | Sep 2008 → Jul 2009 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00483548 | Oct 2007 → Dec 2008 | bipolar I disorder, bipolar depression | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00347425 | Dec 2006 → Feb 2008 | schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00265382 | Jun 2006 → Jun 2009 | schizophrenia | Viatris Inc. | Terminated | Missed primary |
| Phase 3 | NCT00421954 | May 2006 → May 2008 | bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT00312494 | Apr 2006 → Dec 2008 | bipolar disorder | Viatris Inc. | Completed | Missed primary |
| Phase 3 | NCT00265330 | Mar 2006 → Jan 2008 | bipolar disorder | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00403546 | Jan 2006 → May 2011 | schizophrenia | Donald C. Goff, MD | Completed | Missed primary |
| Phase 3 | NCT00257166 | Jan 2006 → Jul 2007 | bipolar disorder | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00280566 | Dec 2005 → May 2008 | bipolar I disorder, manic bipolar affective disorder | Viatris Inc. | Completed | Met primary |
| Phase 3 | NCT00197951 | Oct 2004 → Apr 2007 | alcohol dependence, anxiety, depressive disorder | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00645229 | Sep 2004 → Mar 2005 | schizoaffective disorder, schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00645372 | Jul 2004 → May 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00143351 | Jun 2003 → Sep 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00645515 | Jun → Dec 2003 | schizophrenia | Viatris Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00145444 | Mar 2003 → Nov 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00136994 | Mar 2003 → Nov 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00649844 | Jan 2003 → Sep 2004 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00139737 | Mar 2002 → Jun 2009 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00159770 | Nov 2001 → Sep 2004 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00174447 | Oct 2001 → Oct 2008 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 437 trials · 1 met primary · 3 missed | ||||||
| Phase 4 | NCT04446234 | May 2021 → Dec 2022 | schizophrenia | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT02935998 | Oct 2016 → Dec 2017 | schizophrenia | Yang Fude | Unknown | No outcome recorded |
| Phase 4 | NCT02307396 | Feb 2015 → Jun 2016 | schizoaffective disorder, schizophrenia | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT01893229 | Sep 2013 → Dec 2015 | bipolar disorder | Guiyun Xu | Unknown | No outcome recorded |
| Phase 4 | NCT01293825 | Jan 2011 → Aug 2012 | bipolar disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01198353 | Sep 2010 → Jun 2013 | schizoaffective disorder, schizophrenia | Soonchunhyang University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01172652 | Apr 2010 → Oct 2011 | bipolar disorder, generalized anxiety disorder, panic disorder | VA Palo Alto Health Care System | Completed | Missed primary |
| Phase 4 | NCT01016145 | Apr 2009 → Jun 2010 | psychotic disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00835107 | Feb 2009 → Jun 2011 | bipolar depression | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT00748566 | Dec 2008 → May 2012 | psychotic disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00786318 | Sep 2008 → Jul 2011 | delirium, psychotic disorder | George Washington University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01000402 | Feb 2008 → Oct 2012 | attention deficit-hyperactivity disorder, bipolar disorder | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| Phase 4 | NCT00472641 | Jan 2007 → Dec 2009 | bipolar disorder | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00406315 | Nov 2006 → Dec 2008 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00329108 | Nov 2006 → Jul 2007 | manic bipolar affective disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00338949 | Jun 2006 → Dec 2009 | metabolic syndrome X, schizophrenia | Veterans Medical Research Foundation | Completed | Missed primary |
| Phase 4 | NCT00374543 | Feb 2006 → Oct 2007 | bipolar disorder, generalized anxiety disorder | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00458211 | May 2005 → Apr 2008 | schizoaffective disorder, schizophrenia | Bronx Psychiatric Center | Completed | No outcome recorded |
| Phase 4 | NCT00297960 | Apr 2005 → ? | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00237666 | Feb 2005 → Feb 2008 | bipolar II disorder, major depressive disorder | The Medical Research Network | Completed | Met primary |
| Phase 4 | NCT00351000 | Jan 2005 → Mar 2007 | schizophrenia | North Suffolk Mental Health Association | Completed | Missed primary |
| Phase 4 | NCT00137020 | Nov 2004 → Apr 2006 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00649064 | Dec 2003 → Sep 2004 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00199940 | Dec 2003 → Apr 2007 | mood disorder, schizophrenia | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 4 | NCT00224315 | Nov 2003 → Sep 2006 | schizophrenia | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| Phase 4 | NCT00159757 | Nov 2003 → Feb 2005 | schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00650429 | Oct 2003 → May 2005 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00645320 | Aug 2003 → Aug 2004 | psychotic disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00644800 | Jul 2003 → May 2004 | delusional disorder, manic bipolar affective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00239109 | Apr 2003 → Feb 2007 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00208208 | Dec 2002 → Apr 2005 | post-traumatic stress disorder | Creighton University | Completed | No outcome recorded |
| Phase 4 | NCT00048802 | Aug 2002 → Aug 2006 | bipolar disorder | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00181922 | Mar 2002 → Dec 2004 | manic bipolar affective disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00418171 | Feb 2002 → Apr 2007 | schizophrenia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00034801 | Sep 2001 → Mar 2003 | depressive disorder, schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00014001 | Dec 2000 → Dec 2004 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | Mixed |
| Phase 4 | NCT01157559 | ? → Jun 2008 | schizophrenia | Chonbuk National University Hospital | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04076371 | Jan 2012 → Dec 2018 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT00818298 | Jan 2009 → Jan 2011 | schizoaffective disorder, schizophrenia | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT00225498 | Jun 2002 → Oct 2008 | schizophrenia | Northwell Health | Completed | No outcome recorded |
| — | NCT00205725 | Nov 2000 → Oct 2006 | schizophrenia, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| Comparator or background therapy46 trials | ||||||
| Phase 0 | NCT03837860 Comparator | Apr 2019 → Mar 2021 | opiate dependence, opioid abuse | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 1 | NCT03565068 Background | Jun 2018 → Apr 2020 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03011645 Comparator | May 2018 → Jan 2020 | cardiovascular disorder | Duke University | Terminated | No outcome recorded |
| Phase 1 | NCT02181803 Background | Aug 2014 → Apr 2015 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00821444 Comparator | Jan → Mar 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03557931 Background | Jul 2018 → Oct 2019 | schizophrenia | Astellas Pharma Global Development, Inc. | Completed | Missed primary |
| Phase 2 | NCT03319953 Background | Dec 2017 → Sep 2019 | schizophrenia | Neurocrine Biosciences | Completed | Missed primary |
| Phase 2 | NCT00555997 Comparator | Mar 2008 → Jun 2010 | major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00509067 Background | Nov 2007 → Mar 2011 | schizophrenia | Georgetown University | Completed | No outcome recorded |
| Phase 2 | NCT00490542 Comparator | Dec 2006 → Aug 2009 | bipolar depression | Tufts Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00096863 Comparator | Dec 2004 → Jul 2007 | delirium | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT00635921 Comparator | Mar 2004 → Apr 2006 | borderline personality disorder | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00650611 Comparator | Dec 2003 → Mar 2005 | bipolar disorder, schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00340379 Comparator | Apr 2003 → Aug 2005 | mood disorder | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT01117220 Comparator | Jun 2010 → Apr 2011 | bipolar disorder | Viatris Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00257192 Comparator | Apr 2006 → Mar 2009 | schizophrenia | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00282464 Comparator | Feb 2006 → Mar 2008 | bipolar I disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00288353 Comparator | Jan 2006 → Dec 2008 | bipolar disorder, schizoaffective disorder, schizophrenia | Northwestern University | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00254202 Comparator | Nov 2005 → Sep 2006 | schizophrenia | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00141271 Comparator | Jul 2005 → Feb 2008 | bipolar disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00177164 Comparator | Nov 2003 → Mar 2008 | bipolar I disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT05741502 Comparator | Aug 2023 → Jan 2026 | schizophrenia | Ohio State University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02282085 Comparator | Dec 2014 → Dec 2017 | schizophrenia | Matt Byerly | Unknown | No outcome recorded |
| Phase 4 | NCT02237417 Comparator | Sep 2014 → Nov 2018 | schizophrenia | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT02040883 Background | Feb → Dec 2014 | schizophrenia | Qingyun Yin | Unknown | No outcome recorded |
| Phase 4 | NCT01844700 Comparator | Jul 2013 → Apr 2014 | obesity due to melanocortin 4 receptor deficiency | Northwell Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01185743 Comparator | Jul 2010 → Jan 2017 | diabetes mellitus, schizophrenia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01168674 Comparator | Feb 2010 → Dec 2011 | bipolar disorder, major depressive disorder | Tufts Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01714011 Comparator | May 2009 → Sep 2011 | schizophrenia | University of Malaya | Completed | No outcome recorded |
| Phase 4 | NCT00806234 Comparator | Jan 2009 → Mar 2014 | psychotic disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT02526030 Comparator | Oct 2008 → Feb 2014 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT00622739 Comparator | Feb 2007 → Sep 2009 | bipolar disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00330863 Comparator | May 2006 → Jan 2011 | schizoaffective disorder, schizophrenia | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT02305823 Comparator | Oct 2005 → Feb 2011 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT02534363 Comparator | Oct 2005 → Jan 2011 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT00634348 Comparator | Apr 2004 → Mar 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00148564 Comparator | Mar 2004 → Mar 2007 | schizophrenia | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00932529 Comparator | Feb 2003 → Jan 2010 | psychotic disorder | University of Bergen | Completed | No outcome recorded |
| Phase 4 | NCT00044655 Comparator | Jul 2001 → Mar 2009 | schizophrenia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| — | NCT02192723 Comparator | Jun 2012 → Jun 2014 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT01485692 Comparator | Feb 2009 → Mar 2011 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00910988 Comparator | Feb 2009 → Jun 2012 | hyperglycemia, hyperlipidemia | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00538642 Comparator | Aug 2007 → Apr 2011 | bipolar disorder, schizoaffective disorder, schizophrenia | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT00229385 Comparator | Jan 2006 → Apr 2008 | obsessive-compulsive disorder, schizophrenia | Sheba Medical Center | Completed | No outcome recorded |
| — | NCT00288366 Comparator | Jan 2006 → Dec 2008 | bipolar disorder, schizoaffective disorder, schizophrenia | Northwestern University | Completed | No outcome recorded |
| — | NCT00515723 Comparator | Sep 2001 → Dec 2008 | hyperglycemia, schizoaffective disorder, schizophrenia, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2012-08-22 | Wockhardt | Regulatory WOCKHARDT RECEIVES TENTATIVE US FDA APPROVAL FOR GENERIC VERSION OF ANTI – PSYCHOTIC DRUG GECDON® wockhardt.com ↗
Pharmaceutical and biotechnology major Wockhardt has received tentative US FDA approval for marketing a generic version of 20mg, 40mg, 60mg & 80mg capsules containing Ziprasidone hydrochloride, which is used in the treatment of bipolar disorders and schizophrenia. |
| 2006-12-01 | Eli Lilly and Company | Results Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial lilly.com ↗
Zyprexa was less costly by about $2,700 per year than quetiapine, $1,212 per year less than risperidone, and $3,564 per year less than ziprasidone. |
| 2006-04-01 | Eli Lilly and Company | Results CATIE Phase 2 Data Confirm Patients Stay on Treatment Longer Because of Symptom Improvement More So Than Tolerability lilly.com ↗
In the tolerability arm, risperidone and Zyprexa performed best in terms of all-cause discontinuation, which was contrary to the study's hypothesis that ziprasidone would be the most effective atypical because it caused little or no weight gain(ii). |
| 2005-09-19 | Eli Lilly and Company | Results According to CATIE, Zyprexa(R) More Effective on Discontinuation Rate than Other Antipsychotics Studied lilly.com ↗
CATIE found that for Zyprexa the average time to discontinuation was 9.2 months as compared with 4.6 months for quetiapine, 4.8 months for risperidone, 3.5 months for ziprasidone and 5.6 months for perphenazine. |
| 2005-05-23 | Eli Lilly and Company | Results New Study Showed Efficacy was Most Important Factor in Decision to Stay on Antipsychotic Treatment for Schizophrenia lilly.com ↗
People taking atypical antipsychotics for schizophrenia were most likely to discontinue therapy due to continued presence of psychiatric symptoms, according to data presented today at the 158th annual meeting of the American Psychiatric Association (APA). |
| 2005-04-06 | Eli Lilly and Company | Results Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics lilly.com ↗
One of the studies revealed that patients taking olanzapine or clozapine remained on treatment longer than other atypicals (risperidone, quetiapine, ziprasidone) or the typical perphenazine. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-08-22 | Wockhardt | WOCKHARDT RECEIVES TENTATIVE US FDA APPROVAL FOR GENERIC VERSION OF ANTI – PSYCHOTIC DRUG GECDON® wockhardt.com ↗ |
| 2006-12-01 | Eli Lilly and Company | Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial lilly.com ↗ |
| 2006-04-01 | Eli Lilly and Company | CATIE Phase 2 Data Confirm Patients Stay on Treatment Longer Because of Symptom Improvement More So Than Tolerability lilly.com ↗ |
| 2005-09-19 | Eli Lilly and Company | According to CATIE, Zyprexa(R) More Effective on Discontinuation Rate than Other Antipsychotics Studied lilly.com ↗ |
| 2005-05-23 | Eli Lilly and Company | New Study Showed Efficacy was Most Important Factor in Decision to Stay on Antipsychotic Treatment for Schizophrenia lilly.com ↗ |
| 2005-04-06 | Eli Lilly and Company | Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics lilly.com ↗ |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 127 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ziprasidone | “Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗124“There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment...” NCT00159757 ↗ “Thirty patients will receive ziprasidone treatment, in progressively increasing doses, starting from 40 mg per day, and the other 30 patients will receive placebo” NCT00197951 ↗ “Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.” NCT03319953 ↗ “Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics” NCT05741502 ↗ “Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.” NCT00338949 ↗ “Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder” NCT00177164 ↗ “Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg” NCT01016145 ↗ “Ziprasidone is an atypical antipsychotic recommended to be administered twice daily.” PMID 23417515 ↗ Feb 2013 “switched to Zoladine capsules (ziprasidone hydrochloride capsules)” NCT04975035 ↗ “Ziprasidone(according to response, and tolerance)40-160mg” NCT01000402 ↗ |
| Known as | CP-88, 059-27 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | CP-88,059-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | CP-88059 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Geodon | “Patients will be switched from their current antipsychotic medication to aripiprazole (Abilify) or ziprasidone (Geodon) (unless clinically contraindicated) for comparison with...” NCT00288366 ↗13“The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently...” NCT00237666 ↗ “This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.” NCT00282464 ↗ “This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients” NCT00421954 ↗ “Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify)” NCT00177164 ↗ “Geodon (Ziprasidone) for Posttraumatic Stress Disorder” NCT00208208 ↗ “ziprasidone HCI(Geodon®)” NCT02237417 ↗ “ziprasidone (Geodon)” NCT00181922 ↗ “ziprasidone (Geodon)” NCT00490542 ↗ “ziprasidone (Geodon)” NCT00288353 ↗ “Ziprasidone/Geodon” NCT00472641 ↗ |
| Known as | NSC-760351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Zeldox | “Geodon, Zeldox” NCT00650429 ↗ |
| Known as | ZIP | “5. 220 begin double-blind treatment with ziprasidone (ZIP)” NCT00014001 ↗ |
| Known as | Zipradon | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidona | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | ziprasidone HCI | “ziprasidone HCI(Geodon®)” NCT02237417 ↗ |
| Known as | ziprasidone hydrochloride | “switched to Zoladine capsules (ziprasidone hydrochloride capsules)” NCT04975035 ↗ |
| Known as | Ziprasidone hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone hydrochloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone mesilate trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | ZIPRASIDONE MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Ziprasidone mesylate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL708 ↗ |
| Known as | Zoladine | “switched to Zoladine capsules (ziprasidone hydrochloride capsules)” NCT04975035 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL708 ↗ |
| Modality | Small molecule | — CHEMBL708 ↗ |
| Route | Oral | “oral liquid formulations of haloperidol versus ziprasidone versus placebo” NCT00096863 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL708 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL708 ↗ |
| Target | HTR2C | “antagonist (ziprasidone) to reduce cortisol response to mental and metabolic stress in men carrying the rs6318 C allele and women in the rs6318 CC genotype of 5HTR2C.” NCT03011645 ↗ |